AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Recruitingn/aAges 18 Years - anyAllFundación FLS de Lucha Contra el Sida, las Enferm…
💬

In plain words

What the trial is, and whether it could suit you

The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patients able to understand and sign the informed consent form. * Documented HIV-1 infection. * Under the first line TLD for at least 6 months. * At least 3 months follow-up with CV \>200c/ml. Exclusion Criteria: * Patients \<18 years of age. * Under the first line regime other than TLD. * Patients with active neoplastic processes. * Patients with active opportunistic diseases. * Patients unable to give informed consent.
💊

What it tests

  • Not applicable- observational study
📍

Where

1 site
Hospital Carmelo
Chokwé, Mozambique
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy